As an international peer reviewed journal, the mission of Emerging Microbes & Infections (EMI) is to provide a new integrated forum to allow for the timely dissemination of large amount of information gathered about microbes and infections, especially ones associated with increasing biological and clinical significance and pathogenic frequency. The sheer volume and complexity of such information has gone beyond the scale and scope of existing specialty journals, and thus EMI is committed to bridging the gap between scientific communities in developed and developing countries where most of the emerging microbes and infections have occurred in recent years. EMI will cover relevant topics of critical biological and clinical value including, but not limited to: epidemic surveillance; clinical manifestation; diagnosis and management; cellular and molecular pathogenesis; innate and acquired immune responses between emerging microbes and their hosts; drug discovery, and vaccine development EMI will serve microbiologists, clinicians, public health workers, drug and vaccine developers, as well as policy makers by providing them with updated knowledge encompassing microbes and infections emerging in different countries and regions throughout the world.

本刊为教育部主管、复旦大学主办的学术类期刊，旨在建立一个学科间交叉﹑基础联系临床和公共卫生预防的平台，以利于传播科研成果，培养学科人才和促进国内外学术交流。本刊内容涉及与人类、动物和植物感染相关的微生物，如病毒、细菌、真菌、立克次体、螺旋体、支原体等的生物学及分子生物学特性，抗感染免疫，实验室诊断技术，临床感染及流行病学与防疫等方面的研究。

原发性肝癌发病率居恶性肿瘤的第六位，而死亡率却位列前第三。目前肝癌虽然已可以早期诊断，但由于起病隐袭，且多数肝癌发生于肝硬化基础之上，确诊时能手术治疗的患者仅约40%。对于失去手术机会的患者只能进行射频消融或选择性肝动脉栓塞化疗等介入治疗，此部分患者三年生存率约为20％~40％。进展期患者需采用系统药物治疗。现已有多个分子靶向药物，如索拉非尼、仑伐替尼和瑞格非尼等获得批准用于这部分患者的治疗。加上免疫检查点抑制剂，如纳武利尤单抗和帕博利珠单抗等，有多种药物选择及联合用药方案，已完全改变以往仅有索拉非尼单一药物的局面。目前联合治疗已取得突破性进展，能有效延长患者总生存期或无进展生存期，给进展期肝癌患者带来新的希望。由于肝癌具有高度异质性，现有的生物标记还不能有效预测分子靶向药物或免疫检查点抑制剂的敏感性，因此，迫切需要建立能够反映药物敏感性的体外检测手段，为药物选择提供帮助。